In-Situ Hybridization Market Report 2026

In-Situ Hybridization Market Overview

• In-Situ Hybridization market size has reached to $1.78 billion in 2025 • Expected to grow to $2.76 billion in 2030 at a compound annual growth rate (CAGR) of 9.1% • Growth Driver: Rising Cancer Incidence Driving The Growth Of The Market Due To Increasing Demand For Precise Genetic Detection • Market Trend: Advancements In Diagnostic Solutions Enhancing Targeted Cancer Treatment Through Rapid And Accurate HER2 Testing • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under In-Situ Hybridization Market?

In-situ hybridization (ISH) is a molecular technique used to identify and visualize specific DNA or RNA sequences within preserved cells or tissue sections. It works by applying labeled complementary probes that bind to the target genetic material, allowing researchers to see where specific genes or transcripts are located while maintaining the structure of the tissue. ISH is commonly used in research and clinical settings to study gene expression, detect chromosomal abnormalities, identify viral infections, and support cancer diagnosis, offering detailed spatial and molecular insights within biological samples. The main products of in-situ hybridization include analytical instruments, kits and reagents, software and services, and others. Analytical instruments are specialized devices used to detect, measure, and analyze biological, chemical, or physical properties in a sample. It uses various technologies such as fluorescence in situ hybridization, chromogenic in situ hybridization, and dual-color in situ hybridization and is applied for cancer diagnosis, cytogenetics, developmental biology, infectious diseases, immunology, and others. It is used by various end users, including hospitals and diagnostic laboratories, academic and research institutes, contract research organizations, and pharmaceutical and biotechnology companies.

What Is The In-Situ Hybridization Market Growth Forecast?

The in-situ hybridization market size is expected to see strong growth in the next few years. It will grow to $2.76 billion in 2030 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to rising demand for precision oncology diagnostics, growing integration of ai-driven image analysis, expansion of personalized medicine research, increasing investments in molecular diagnostics infrastructure, development of advanced probe technologies. Major trends in the forecast period include increasing adoption of multiplex ish techniques, rising use of automated slide scanning systems, growing demand for high-resolution spatial gene expression analysis, expansion of digital pathology integration, enhanced focus on companion diagnostics.

Global In-Situ Hybridization Market Segmentation

1) By Product: Analytical Instruments, Kits And Reagents, Software And Services, Other Products 2) By Technology: Fluorescence In Situ Hybridization, Chromogenic In Situ Hybridization, Dual-Color In Situ Hybridization 3) By Application: Cancer Diagnosis, Cytogenetics, Developmental Biology, Infectious Diseases, Immunology, Other Applications 4) By End User: Hospitals And Diagnostic Laboratories, Academic And Research Institutes, Contract Research Organizations, Pharmaceutical And Biotechnology Companies Subsegments: 1) By Analytical Instruments: Fluorescence Microscopes, Brightfield Microscopes, Automated Slide Scanners, Hybridization Systems 2) By Kits And Reagents: DNA Probes, RNA Probes, Labeling Kits, Detection Reagents, Pretreatment Reagents 3) By Software And Services: Image Analysis Software, Data Management Software, Custom Probe Design Services, Sample Preparation Services 4) By Other Products: Slides And Coverslips, Storage Reagents, Hybridization Buffers, Control Probes

What Is The Driver Of The In-Situ Hybridization Market?

The rising incidence of cancer is anticipated to fuel the growth of the in-situ hybridization market in the coming years. Cancer is a condition in which abnormal cells grow uncontrollably and can invade or spread to other body parts. Cancer cases are rising due to increasing life expectancy, as aging allows more time for genetic mutations to accumulate and for individuals to be exposed to cancer-causing factors. In-situ hybridization (ISH) plays a key role in cancer management by enabling the detection of specific genetic abnormalities within tumor cells. It is used for accurate diagnosis, prognosis, and guiding targeted therapy decisions. For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, new cancer cases are projected to exceed 35 million in 2050, marking a 77% increase from the estimated 20 million cases in 2022. Therefore, the rising incidence of cancer will boost the growth of the in-situ hybridization industry.

Key Players In The Global In-Situ Hybridization Market

Major companies operating in the in-situ hybridization market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Danaher Corporation, Merck KGaA, Agilent Technologies Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Qiagen NV, Bio-Techne Corporation, Leica Biosystems Nussloch GmbH, Biocare Medical LLC, BioGenex Srl, Oxford Gene Technology Inc., Creative Biolabs, Empire Genomics LLC, Abnova Corporation, BioView Ltd., Advanced Cell Diagnostics Inc., BioCat GmbH, Bio SB Inc., Genemed Biotechnologies Inc.

Global In-Situ Hybridization Market Trends and Insights

Major companies operating in the in-situ hybridization market are focusing on developing advanced solutions, such as HER2 testing solutions, to help predict patient response to targeted therapies. HER2 testing solutions are diagnostic tools used to identify the presence and level of the HER2 protein in cancer cells, helping guide targeted treatment decisions. For instance, in December 2023, Cytelabs, an India-based cancer diagnostic services provider, launched dual in situ hybridization (DISH) testing for breast cancer patients. DISH technology, approved by the US FDA, represents a significant advancement in accurate HER2 testing, which is vital for targeted breast cancer treatment. It notably decreases the waiting time by providing HER2 status results within 24 to 48 hours, helping to ease the stress experienced by patients and their families. By offering dependable results quickly, DISH allows prompt treatment planning and initiation. Since HER2 status plays a crucial role in determining prognosis and therapy, precise and efficient testing is essential for the proper evaluation of all invasive breast cancers.

What Are Latest Mergers And Acquisitions In The In-Situ Hybridization Market?

In January 2025, Leica Biosystems, a Germany-based biotechnology company, partnered with Molecular Instruments to facilitate complete RNA-ISH procedures with the BOND RX and BOND RXm research staining systems. The collaboration between Leica Biosystems and MI combines HCR Pro RNA-ISH with existing BOND immunohistochemistry and immunofluorescence techniques, allowing simultaneous detection of RNA and proteins in the same tissue sample. This innovation helps researchers obtain more detailed spatial information while preserving limited tissue resources. Molecular Instruments is a US-based biotechnology company.

Regional Outlook

North America was the largest region in the in-situ hybridization market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the In-Situ Hybridization Market?

The in-situ hybridization market consists of revenues earned by entities by providing services such as custom probe design, tissue sample preparation, assay development, multiplexing services, and validation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The in-situ hybridization market also includes sales of slide processing equipment, positive and negative control slides, hybridization chambers, and nuclease-free consumables. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the In-Situ Hybridization Market Report 2026?

The in-situ hybridization market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the in-situ hybridization industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.